We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medidata Solutions & University of Carolina Wilmington Tie Up
Read MoreHide Full Article
Medidata Solutions Inc. , a NY-based global provider of clinical and cloud-based solutions for life sciences companies, announced a strategic partnership with University of North Carolina Wilmington (UNCW) to introduce its advanced cloud-based technology to the UNCW clinical research scholars.
This is a three-year agreement through which UNCW students will gain complete access to Medidata’s industry-leading technologies like Medidata Clinical Cloud pro bono, Medidata Rave and iMedidata, forming a single platform unifying medicine, science and technology.
Additionally, the students will get formal training of the cloud based solutions in Medidata’s eLearning platform, the Medidata Academy to enhance their clinical analysis skills. However, all the other terms of the agreement have been kept under wraps.
Meanwhile, a glimpse at the share price movement reveals that Medidata rallied 1.3% to close at $54.08 following the news.
As per management, the partnership will exclusively focus on skill enhancement of next-generation research scholars by providing them with a pragmatic exposure to lab analysis. Notably, 80 students have already been enrolled and will be annually trained on Medidata’s platform.
Our Take
In the recent past, Medidata witnessed several notable developments which include the commercial partnership with SHYFT analytics, launch of mHealth stroke study in collaboration with China-based Techfields Pharma and adoption of the company’s flagship Medidata Rave by Israeli-based Pluristem Therapeutics.
In our view, Medidata diversifies its core business through strategic tie-ups and partnerships. In fact, the share price movement trend has been quite attractive, as it represents a strong one-year return of 11.6%, better than the S&P 500’s 6.5% over the same time frame.
We note that the global sentiments for the eClinical solutions (cloud-based) market represent a lucrative scenario, as it is forecasted to reach a worth of $5.9 billion by 2020, growing at a CAGR of 12.1% (Markets And Markets). Buoyed by this huge market prospect, Medidata is set to gain significant market traction in the coming quarters.
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medidata Solutions & University of Carolina Wilmington Tie Up
Medidata Solutions Inc. , a NY-based global provider of clinical and cloud-based solutions for life sciences companies, announced a strategic partnership with University of North Carolina Wilmington (UNCW) to introduce its advanced cloud-based technology to the UNCW clinical research scholars.
This is a three-year agreement through which UNCW students will gain complete access to Medidata’s industry-leading technologies like Medidata Clinical Cloud pro bono, Medidata Rave and iMedidata, forming a single platform unifying medicine, science and technology.
Additionally, the students will get formal training of the cloud based solutions in Medidata’s eLearning platform, the Medidata Academy to enhance their clinical analysis skills. However, all the other terms of the agreement have been kept under wraps.
MEDIDATA SOLUTN Price
MEDIDATA SOLUTN Price | MEDIDATA SOLUTN Quote
Meanwhile, a glimpse at the share price movement reveals that Medidata rallied 1.3% to close at $54.08 following the news.
As per management, the partnership will exclusively focus on skill enhancement of next-generation research scholars by providing them with a pragmatic exposure to lab analysis. Notably, 80 students have already been enrolled and will be annually trained on Medidata’s platform.
Our Take
In the recent past, Medidata witnessed several notable developments which include the commercial partnership with SHYFT analytics, launch of mHealth stroke study in collaboration with China-based Techfields Pharma and adoption of the company’s flagship Medidata Rave by Israeli-based Pluristem Therapeutics.
In our view, Medidata diversifies its core business through strategic tie-ups and partnerships. In fact, the share price movement trend has been quite attractive, as it represents a strong one-year return of 11.6%, better than the S&P 500’s 6.5% over the same time frame.
We note that the global sentiments for the eClinical solutions (cloud-based) market represent a lucrative scenario, as it is forecasted to reach a worth of $5.9 billion by 2020, growing at a CAGR of 12.1% (Markets And Markets). Buoyed by this huge market prospect, Medidata is set to gain significant market traction in the coming quarters.
Zacks Rank & Key Picks
Currently, Medidata has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include INC Research Holdings Inc. (INCR - Free Report) , Lantheus Holdings Inc (LNTH - Free Report) and NuVasive Inc. . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>